Kyprolis

Pronunciation: pronunciation varies by local usage.

Generic name: carfilzomib
Brand names: KYPROLIS
Drug class: Proteasome inhibitor
Form: Lyophilized powder for reconstitution in single-dose vials (10 mg, 30 mg, or 60 mg)
Route: Intravenous infusion
Legal status: Prescription-only medicine

Availability and supply rules vary by country

Trade names by country: United States · Canada

What carfilzomib is and how it works

Carfilzomib is a proteasome inhibitor that is given by intravenous infusion. It is approved for the treatment of adult patients with relapsed or refractory multiple myeloma, used in combination with dexamethasone, lenalidomide, daratumumab, or isatuximab, or as a single agent (monotherapy). (1)

Kyprolis is administered as part of a treatment regimen determined by a specialist oncologist. It requires specific dosing schedules, premedication, and hydration; it is not self-administered. The patient must be monitored closely for serious side effects during and after infusion.

Mechanism of action: how carfilzomib works

The reviewed source describes carfilzomib as a proteasome inhibitor. No further pharmacological details are provided. (1)

What carfilzomib is used for

Relapsed or refractory multiple myeloma

Kyprolis is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma. It may be used in combination with dexamethasone, lenalidomide, daratumumab, or isatuximab, or as a single agent (monotherapy). The choice of regimen and dosing schedule is individually determined by the treating oncologist. (1)

Before taking carfilzomib

Do not take / not appropriate for

No contraindications are listed in the reviewed US prescribing information. Treatment is initiated and supervised by a specialist after assessing individual patient factors. (all uses) (1)

Tell your clinician about

Any history of heart disease, heart failure, or previous cardiac events.
Any lung or breathing problems, including acute respiratory distress syndrome.
Liver disease or abnormal liver function tests.
Risk factors for tumor lysis syndrome (e.g., high tumor burden).
Pregnancy or plans to become pregnant; effective contraception is required.
Breastfeeding plans.
All medications, including over-the-counter and supplements (interactions have not been fully reviewed).

(1)

How to take carfilzomib

Kyprolis is given as an intravenous infusion by a healthcare professional in a clinical setting. The specific dosing schedule, premedication, and hydration plan are determined by the treating oncologist.
The patient does not self-administer the infusion. Do not attempt to prepare or administer this medication at home.
Premedication with dexamethasone is required to reduce the risk of infusion reactions.
Adequate hydration is mandatory before dosing in Cycle 1: oral fluids (30 mL/kg at least 48 hours before Cycle 1 Day 1) and intravenous fluids (250–500 mL of appropriate IV fluid prior to each dose in Cycle 1).

(1)

Procedures and treatment changes

Tell the treating team before surgery, procedures, or any medicine change. Do not alter treatment without the responsible clinician. (1)

Missed dose

Kyprolis is administered according to a scheduled treatment plan. If a dose is missed or delayed, contact the treating clinic immediately for rescheduling instructions. Do not attempt to self-administer or adjust the next dose.

Overdose

No specific overdose-management protocol is provided in the reviewed source. How the treating healthcare team would manage a suspected overdose is not established and remains unresolved. Seek emergency medical attention if serious symptoms occur. (1)

Side effects

Adverse reactions can vary depending on whether Kyprolis is used as monotherapy or in combination with other drugs. The most common side effects include anemia, fatigue, thrombocytopenia, nausea, and dyspnea. Serious and potentially life-threatening reactions can also occur.

Anemia

What to notice: Low red blood cell count, which may cause tiredness, weakness, shortness of breath, or pale skin.

What to do: Blood counts will be monitored regularly. Tell the treatment team if you notice severe or worsening symptoms. (1)

Fatigue

What to notice: Persistent tiredness or lack of energy that interferes with daily activities.

What to do: Report severe or debilitating fatigue to the treatment team. (1)

Thrombocytopenia

What to notice: Low platelet count, which can cause easy bruising, bleeding gums, or nosebleeds.

What to do: Platelet levels will be monitored. Inform the team of any unusual bleeding or bruising. (1)

Nausea

What to notice: Feeling sick to the stomach, with or without vomiting.

What to do: Anti-nausea medications may be prescribed. Report persistent or severe nausea. (1)

Dyspnea

What to notice: Shortness of breath or difficulty breathing.

What to do: Report any new or worsening breathing difficulty immediately to the treatment team. (1)

Cardiac symptoms

What to notice: Chest pain or pressure, swelling of the legs, rapid weight gain, palpitations, or sudden shortness of breath.

What to do: Seek medical attention immediately; cardiac toxicity can be serious. (1)

Pulmonary toxicity

What to notice: Acute breathing difficulty, rapid breathing, or bluish skin (possible acute respiratory distress syndrome or acute respiratory failure).

What to do: Requires immediate emergency medical evaluation. Treatment may be discontinued by the clinician. (1)

Hepatic toxicity

What to notice: Yellowing of skin or eyes, dark urine, severe fatigue, or abdominal pain.

What to do: Contact the treatment team urgently. Liver function tests will be checked. (1)

Tumor lysis syndrome

What to notice: Nausea, vomiting, muscle cramps, seizures, or reduced urine output.

What to do: Promptly inform the treatment team; this condition requires immediate management. (1)

Thrombotic microangiopathy

What to notice: Fever, neurological changes, bruising, or kidney problems.

What to do: Report immediately; treatment may need to be discontinued if suspected. (1)

Serious warnings

Cardiac toxicity — emergency

Symptoms: Chest pain, palpitations, shortness of breath, swelling of the legs, or sudden weight gain. Heart failure, heart attack, or cardiac arrest can occur.

Action: Seek emergency medical help if symptoms develop. The treating oncologist may withhold Kyprolis for Grade 3–4 cardiac reactions; further dosing decisions are made by the treating clinician. (1)

Pulmonary toxicity — emergency

Symptoms: Acute breathing difficulty, rapid breathing, or bluish skin (acute respiratory distress syndrome, acute respiratory failure, or diffuse infiltrative pulmonary disease).

Action: Seek emergency medical attention immediately. The treating clinician will decide whether Kyprolis is discontinued if pulmonary toxicity is suspected. (1)

Infusion reactions — prompt_medical_attention

Symptoms: Symptoms during or shortly after infusion may include chills, fever, hypotension, or breathing difficulty. Premedication with dexamethasone is given to reduce risk.

Action: The healthcare team will manage reactions during infusion. If symptoms occur after leaving the clinic, seek medical help. (1)

Interactions

Medicine or test	Effect	Action
No specific drug interactions identified	The reviewed source does not provide a detailed drug interaction list. Whether specific concomitant medicines require additional monitoring is not established in the reviewed source and remains unresolved.	Give the treating oncologist a complete list of all medications, supplements, and herbal products. (1)

Pregnancy, breastfeeding, kidney/liver function, age

Pregnancy

Kyprolis can cause fetal harm. Inform the doctor if you are pregnant or planning pregnancy. Effective contraception is required during treatment and for 6 months after the last dose for females of reproductive potential, and for males with female partners of reproductive potential, effective contraception is required during treatment and for 3 months after the last dose. (1)

Breastfeeding

Women should not breastfeed during treatment with Kyprolis and for 2 weeks after the last dose, due to the potential for serious adverse reactions in the infant. (1)

Pediatric use

No pediatric dosing information is available in the reviewed source. Whether Kyprolis is approved for use in children is not established and remains unresolved; use in children should only be considered under specialist guidance. (1)

Monitoring

Before starting

Baseline cardiac evaluation, including assessment of heart failure risk.
Liver function tests.
Assessment of tumor burden and risk of tumor lysis syndrome.
Ensure adequate hydration plan and premedication with dexamethasone.
Review of concomitant medications and any history of pulmonary disease.

During treatment

Monitor clinically for signs and symptoms of cardiac failure or ischemia during and after infusions.
Monitor for respiratory symptoms; conduct pulmonary evaluation if ARDS or acute respiratory failure is suspected.
Regular liver enzyme monitoring; the treating clinician will decide whether to withhold dosing if hepatic toxicity is suspected.
Monitor for tumor lysis syndrome; manage promptly.
Observe for signs of thrombotic microangiopathy (e.g., TTP); the treating clinician will decide whether Kyprolis should be discontinued if this is suspected.
Hydration and premedication protocols must be followed per cycle.

(1)

Storage

Storage instructions are not provided in the reviewed source. Kyprolis is stored and prepared by the healthcare facility according to manufacturer guidelines.

Professional information

Clinician-facing context only. Use the current local prescribing information and specialist guidelines for treatment decisions.

United States (FDA-approved labeling; not confirmed for other regions)

Indication: Relapsed or refractory multiple myeloma

Dose summary: Per the reviewed US FDA prescribing information, three dosing schedules are approved: 20/70 mg/m² once weekly (30-minute infusion); 20/56 mg/m² twice weekly (30-minute infusion); 20/27 mg/m² twice weekly (10-minute infusion). Each regimen starts with 20 mg/m² on Cycle 1, Day 1; if tolerated, the dose is escalated to the higher target dose starting Cycle 1, Day 8. Adequate hydration is required in Cycle 1 (oral and intravenous). The choice of regimen is individualized. No non-US regulatory label was reviewed.

Renal context: No renal or hepatic impairment dose adjustment guidance is provided in the reviewed source. Specialist assessment is required. (1)

Mechanism of action

Hepatic guidance

Regular liver enzyme monitoring is required; no specific hepatic impairment dose adjustment is provided. Use specialist judgement.

Overdose note

No specific overdose protocol is provided in the reviewed source. Management approach is not established and remains unresolved. (1)

Frequently asked questions

Can Kyprolis be administered at home?

No. Kyprolis is given as an intravenous infusion by a healthcare professional in a clinic or hospital. It is not intended for home use. (1)

What are the most common side effects of Kyprolis?

The most common side effects (occurring in at least 20% of patients) when used alone include anemia, fatigue, thrombocytopenia, nausea, and dyspnea. Side effects may differ when used in combination with other medications. (1)

What should I do if I experience chest pain or shortness of breath during treatment?

Chest pain and breathing difficulties can be signs of serious cardiac or pulmonary toxicity. Seek immediate emergency medical attention and inform your treatment team. (1)

What is the mechanism of action of carfilzomib?